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Background: Recently, three prospective randomized trials have shown that adjuvant radiotherapy (ART) after
radical prostatectomy for the patients with pT3 and/or positive margins improves biochemical progression-free
survival and local recurrence free survival. But, the optimal management of these patients after radical
prostatectomy is an issue which has been debated continuously. The object of this study was to determine the
necessity of adjuvant radiotherapy (ART) by reviewing the outcomes of observation without ART after radical
prostatectomy (RP) in patients with pathologic indications for ART according to the American Urological Association
(AUA)/American Society for Radiation Oncology (ASTRO) guideline.
Methods: From a prospectively maintained database, 163 patients were eligible for inclusion in this study. These
men had a pathological stage pT2–3 N0 with undetectable PSA level after RP and met one or more of the three
following risk factors: capsular perforation, positive surgical margins, or seminal vesicle invasion. We excluded the
patients who had received neoadjuvant hormonal therapy or adjuvant treatment, or had less than 24 months of
follow-up. To determine the factors that influenced biochemical recurrence-free (BCR), univariate and multivariate
Cox proportional hazards analyses were performed.
Results: Among the 163 patients, median follow-up was 50.5 months (24.0-88.2 months). Of those men under
observation, 27 patients had BCR and received salvage radiotherapy (SRT). The multivariate Cox analysis showed that
BCR was marginally associated with pre-operative serum PSA (P = 0.082), and the pathologic GS (HR, 4.063;
P = 0.001) was an independent predictor of BCR. More importantly, in 87 patients with pre-operative PSA < 6.35
ng/ml and GS ≤ 7, only 3 developed BCR.
Conclusions: Of the 163 patients who qualified for ART based on the current AUA/ASTRO guideline, only 27
(16.6%) developed BCR and received SRT. Therefore, using ART following RP using the current recommendation
may be an overtreatment in an overwhelming majority of the patients.
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Prostate cancer (PCa) is the most common noncuta-
neous cancer in men in the United States [1]. Most
newly diagnosed patients present with clinically localized
tumor and undergo radical prostatectomy (RP) [2].
However, approximately 20% of patients treated with RP
have adverse pathologic features, defined as positive sur-
gical margins (PSMs), extracapsular extension (ECE),
seminal vesicle invasion (SVI), and/or lymph node inva-
sion (LNI) [3,4]. Recently, in these patients with high-risk
pathologic factors, the American Urological Association
(AUA) and American Society for Radiation Oncology
(ASTRO) have jointly recommended that adjuvant radio-
therapy (ART) be offered [5].
The support from the AUA and ASTRO for ART are
largely based on three prospective randomized trials that
have shown that ART after RP for the patients with pT3
and/or PSMs improves biochemical recurrence-free sur-
vival [6-8]. Although the results of these trials support
the benefit of ART for selected patients, a recent treat-
ment patterns analysis showed that ART are applied in
less than 20% of the patients with adverse pathologic
characteristics and most patients were closely observed
with serial PSA tests and offered salvage RT (SRT) only
when there was a rise in PSA [9,10]. This reluctance to
widely adopt ART might be attributed to the bias of uro-
logic surgeons on the perceived toxicity of radiotherapy.
Moreover, recent data demonstrated that patients with
PSM who underwent SRT after biochemical recurrence
(BCR) had similar long-term outcomes to those who had
adjuvant radiotherapy and recurred [11,12].
The optimal role of ART after RP is an issue that has
been debated continuously as there is a real risk of com-
plications following radiotherapy [7]. The aim of this
study was to evaluate how many men will potentially ex-
perience overtreatment using the current ASTRO/AUA
guideline for ART. We report that an overwhelming ma-




This study was reviewed and approved by the institu-
tional review board of the Rutgers Cancer Institute of
New Jersey (RCINJ) (No. 0220080225). Furthermore, the
principles of the Helisinki Declaration were followed.
The board exempted informed consent because it was a
retrospective study.
Patient selection and clinical follow-up
We reviewed our prospectively maintained database of
the 930 patients who underwent RP for clinically local-
ized PCa at the Rutgers Cancer Institute of New Jersey
(RCINJ), New Brunswick, NJ by a single surgeon. Usingthe ASTRO/AUA guideline for ART [5], 163 patients
were eligible for inclusion in this study. The inclusion
criteria were: pathologic stage pT2–3 N0M0 with un-
detectable PSA level immediately after the operation and
met one or more of the following three risk factors:
ECE, PSMs, or SVI. We excluded patients who had re-
ceived neoadjuvant hormonal therapy or adjuvant treat-
ment, or had less than 24 months of follow-up. All
patients were evaluated postoperatively every three
months for the first year, every six months for the sec-
ond year, and yearly thereafter with serum PSA and
physical examination. BCR was defined as two consecu-
tive rises in PSA with the last PSA ≥ 0.2 ng/ml.
Pathologic evaluation
The prostatectomy specimens were processed by having
the external surface inked and step sectioned every
4 mm transversely. The prostate apex was examined by
sectioning the tissue sagitally. Following staining with
hematoxylin and eosin, Gleason score (GS), pathologic
stage, and surgical margin status were assessed. Pathologic
staging used the 2002 TNM classification. A PSM was de-
fined as the unequivocal presence of tumor at the inked
margin of the surgically removed prostate. “Quasi-con-
tact” or “close-by” margins were regarded as negative [13].
Radiotherapy technique
When required, adjuvant radiation therapy was delivered
to the prostate bed using IMRT (intensity modulated ra-
diation therapy) technique, using either a Varian linear
accelerator or Tomotherapy machine. The radiation
dose and schedule were standard, at 60 Gy delivered in
2 Gy fractions, five days a week. The CTV (clinical tar-
get volume) extended inferiorly as low as the superior
aspect of the penile bulb; superiorly it extended to just
above the pubic symphysis (anteriorly) and incorporated
the seminal vesicle remnant (posteriorly). The CTV an-
terior border was at the posterior pubis symphysis, and
the posterior border was the anterior rectum. The PTV
(planning target volume), to which radiation dose was
actually directed, was made by expanding the CTV by
1.2 cm in all directions, except posteriorly (0.8 cm to
spare rectum).
Statistical analysis
A total of 163 patients were divided into two groups ac-
cording to the status of BCR and compared in terms of
clinical and pathologic data. Independent sample Stu-
dent’s t-test and the Pearson chi-square test were used
to compare continuous and categorical variables, re-
spectively. Kaplan-Meier survival curves were calculated,
and the differences were assessed using the log-rank test.
The area under the receiver operator characteristic curve
(ROC) was used to measure predictive of pre-operative
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sensitivity and specificity. Univariate and multivariate
Cox proportional hazard models were created to control
for predictors of BCR. Hazard ratio (HR) and 95% confi-
dence interval (CI) were computed. Statistical analysis
was performed by using SPSS 12.0 software (SPSS Inc.,
Chicago, IL, USA), and a two-sided P value < 0.05 was
considered to be statistically significant.
Results
The median follow-up was 50.5 months (24.0-88.2 months)
and the associated demographic data is presented in Table 1.
In this cohort, 27 patients had BCR and received SRT dur-
ing the follow-up period. We divided the patients into two
groups according to the status of BCR and compared the
clinical and pathologic factors. There were no significant
differences in age, prostate volume, PSA density, pathologic
stage and PSM rate except for the pre-operative serum PSA
level and surgical Gleason score (GS). Compared to the
BCR-negative group, BCR-positive group had higher pre-
operative serum PSA level (P = 0.006). Simultaneously, the
incidence of BCR in patients with surgical GS ≥ 8 was sig-
nificantly higher than that in men with GS ≤ 7 (P < 0.001).
Because pre-operative serum PSA levels correlated
with the increased rate of BCR, we examined varying
pre-operative PSA cutoffs on BCR. ROC analysis was
carried out and AUC of PSA is shown in Figure 1A. PSATable 1 Characteristics of enroll patients
Variables Bio
Negative (N = 136)
Mean (range) age (yr) 60.3 (43-75)
Mean (range) PSA (ng/mL) 6.4 (1.4-52.4)
Prostate volume (range) (mL) 43.9 (41.5-46.3)
PSA density (range) 0.16 (0.02-0.87)
Surgical GS (%)
6 38 (95.0)
3 + 4 57 (89.1)












GS, Gleason score; aStudent t-test; bLinear by linear association test; cChi-square teslevel >6.35 ng/ml was shown to be a predictive param-
eter for BCR (sensitivity 63.0%, specificity 67.6%). Using
these values patients were classified into high and low
PSA groups. Kaplan-Meier estimates revealed significant
differences in time to BCR between the low and high
PSA groups (log rank test, P = 0.003; Figure 1B). More-
over, patients with GS ≥ 8 were significantly more likely
to experience BCR than those with GS ≤ 7 (log rank test,
P < 0.001; Figure 2A).
By univariate Cox proportional hazards analysis, pre-
operative serum PSA and surgical GS significantly influ-
enced the time to BCR (Table 2). However, multivariate
Cox proportional hazard analysis showed that BCR was
marginally associated with pre-operative serum PSA (P =
0.082) while the surgical GS (HR, 4.063; P = 0.001) was
confirmed to be an independent predictor of BCR.Patient stratification
Based on the Cox proportional hazard analyses, we re-
evaluated the patients according to the risk for BCR. At
first we stratified the patients into favorable and unfavor-
able groups. And the favorable group had GS ≤ 7 and
pre-operative PSA 6.35 ng/mL or less. Kaplan-Meir ana-
lysis revealed significant differences in the interval to
BCR between the favorable and unfavorable group (P =
0.001; Figure 2B). More importantly, in 87 patients whochemical recurrence P





















Figure 1 Pre-operative serum PSA levels correlated with the increased rate of the biochemical recurrence. (A) Optimal cut-off value of
PSA for predicting the biochemical recurrence. (B) Biochemical recurrence-free survival according to PSA level.
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had surgical GS ≤ 7, only three patients recurred.
Discussion
In this study, we assessed the outcome of observation in
men who are recommended to have ART offered follow-
ing RP based on the current ASTRO/AUA guideline [5].
During 50.5 months of median follow-up period, BCR
rate was 16.6%. Therefore, more than 80% of the pa-
tients at our institution who qualified for ART based on
the guideline did not need ART.
To date, three prospective randomized trials have shown
that ART after RP for the patients with pT3 and/or PSMs
consistently reduced the risk of BCR anywhere from 50 to
60% and improved the outcome of local control [6-8].
More recently, an update of the SWOG 8794 trial showed
improved overall survival with ART when compared to
observation [14]. Based on these finding, ASTRO and
AUA jointly published a guideline recommending thatFigure 2 Kaplan-Meir curves predict the biochemical recurrence. (A) B
(B) Eighty-seven patients who met the criteria composed of lower pre-ope
patients had BCR.ART be offered to all men who met the inclusion criteria
of the three aforementioned studies. Notwithstanding, the
SWOG 8794 trial demonstrated no overall survival benefit
for the subset of patients with confirmed undetectable
PSA post-operatively [14]. That is, patients who under-
went SRT after BCR had similar long-term outcome to
those who had ART with undetectable PSA level immedi-
ately after RP. Therefore, these results suggest that ART
in every man with high-risk features post-operatively is
not necessary.
To this end, the present study reported the results of
observation without ART in patients who met the
ASTRO/AUA criteria for ART. An important finding in
our study is that the overall BCR after surgery was very
low (16.6%). The prior randomized trials showed a BCR
rate of 46% to 61.8% in the observation cohort, respect-
ively. This favorable result may be explained in part by
the differences in inclusion criteria and baseline charac-
teristics. Our pre-operative mean serum PSA level wasiochemical recurrence (BCR)-free survival according to Gleason score.
rative PSA cutoff (6.35 ng/ml) and surgical GS≤ 7, there were only 3
Table 2 Cox analyses for BCR
Variables Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age 1.046 (0.978-1.104) 0.107
PSA 3.089 (1.414-6.748) 0.005 2.068 (0.911-4.693) 0.082
(<6.35, ≥6.35)
Post-operative GS (≤7 vs. ≥8) 5.077 (2.355-10.944) < 0.001 4.063 (1.816-9.092) 0.001
Organ confinement 2.235 (0.773-6.463) 0.138
(T2 vs. T3)
Margin status (Negative vs. Positive) 1.419 (0.658-3.062) 0.372
GS, Gleason score; HR, hazard ratio; CI, confidence interval.
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studies. For example, the cohort of Wiegel et al. had
higher pre-operative PSA level (9.4 ng/ml) than our
study patients (6.79 ng/ml) [8]. And the frequency of
men with high PSA (>10 ng/ml) was only 14 (8.6%) in
our study population. In the trial reported by Thompson
et al., the rate of PSA > 10 ng/ml was over 40% [7]. Al-
ternatively, the differences in inclusion criteria may be
the underlying reason for the observed low rate of BCR
in the present cohort. Specifically, our study analyzed
patients who had a pathological stage pT2–3 N0 with
undetectable PSA level immediately after RP and met
one or more of the three following risk factors: ECE,
PMSs, or SVI. Two randomized studies (SWOG and
EORTC trials) for patients with pT2 (R1) or pT3 (R0 or
R1) disease did not require an undetectable PSA level
after RP [6,7]. The third ARO study selected patients
with an undetectable PSA level after RP but limited to
pT3 tumors [8].
Several studies had shown that GS, initial PSA level,
SVI, and PSMs are independent predictors of biochem-
ical progression [15,16]. Our present study also showed
that BCR rate was significantly associated with initial
PSA level and surgical GS. But, there was no significant
association with pathologic stage and surgical margin
status. Since the BCR group patients had significantly
higher pre-operative PSA level and surgical GS, we per-
formed further analysis to identify factors independently
correlated with an increased risk of BCR. The multivari-
ate Cox proportional hazard analysis revealed that GS is
an independent predictor of BCR. In the subsequent
analysis of the favorable group defined as GS ≤ 7 and
pre-operative PSA 6.35 ng/mL or less, BCR was only
3.4%. These results suggest that the criteria for ART
based on the ASTRO/AUA guideline need to be re-
evaluated to avoid significant overtreatment. We recom-
mend that for patients with pre-operative PSA < 6.35,
Gleason score <8, and an undetectable PSA immediately
after surgery, observation is a reasonable approach.
Lastly, the present study has a significant economic
implication. In the U.S., approximately 90 percent ofPCa patients will choose definitive treatment [17], result-
ing in a projected $12 billion in medical costs in 2010
[18]. At the present time, the most widely used modality
for radiation therapy is intensity modulated radiation
therapy (IMRT). The calculated reimbursement for
IMRT as a primary treatment was $29,356 in patients
with low- or intermediate-risk PCa [19]. Other studies
reported that the treatment with IMRT costs $15,000–
$20,000 more than alternative standard therapies [20,21].
Showalter et al. reported that the mean incremental cost
for ART versus observation was $6,023 per patient [22].
Therefore, the minimum direct economic benefit of ob-
servation over ART in the present cohort was $819,128
(136 × $6,023).
Potential limitations of the current study are the retro-
spective study design, relatively small sample size and a
relatively short follow–up period. It should be pointed
out though, that all data in this study were recorded pro-
spectively. Another limitation is that our study is a single
center single surgeon series. Therefore, the impact of
surgical technique and institutional bias cannot be
assessed.Conclusions
The results of our study demonstrated that among 163
patients with a high risk of recurrence based on the
ASTRO/AUA guideline, only 27 patients (16.6%) devel-
oped BCR and received SRT. In addition, in 87 patients
with pre-operative PSA less than 6.35 ng/ml and Glea-
son score <8, only three recurred (3.4%). Therefore,
ART in patients who meet the currently endorsed
ASTRO/AUA criteria should be applied more selectively
to avoid significant overtreatment.
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